Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

Janet Sim, Jonathan T. Sockolosky, Emma Sangalang, Shelley Izquierdo, Darlene Pedersen, William Harriman, Ardian S. Wibowo, Josh Carter, Anup Madan, Laura Doyle, Ons Harrabi, Steven E. Kauder, Amy Chen, Tracy C. Kuo, Hong Wan & Jaume Pons

To cite this article: Janet Sim, Jonathan T. Sockolosky, Emma Sangalang, Shelley Izquierdo, Darlene Pedersen, William Harriman, Ardian S. Wibowo, Josh Carter, Anup Madan, Laura Doyle, Ons Harrabi, Steven E. Kauder, Amy Chen, Tracy C. Kuo, Hong Wan & Jaume Pons (2019): Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα, mAbs, DOI: 10.1080/19420862.2019.1624123

To link to this article: https://doi.org/10.1080/19420862.2019.1624123

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

Janet Sim a, Jonathan T. Sockolosky c, Emma Sangalang a, Shelley Izquierdo b, Darlene Pedersen b, William Harriman a, Aridian S. Wibowo a, Josh Carter c, Anup Madan a, Ons Harrabi a, Steven E. Kauder a, Amy Chen a, Tracy C. Kuo a, Hong Wan a, and Jaume Pons a

a ALX Oncology, Department of Protein Sciences and Translational Biology, Burlingame, CA, USA; b Ligand Pharmaceuticals, Inc, Emeryville, CA, USA; c Helix Biotstructures, Columbus, IN, USA; d Covance Genomics Laboratory, Redmond, WA, USA

ABSTRACT
Targeting the CD47-signal-regulatory protein α (SIRPα) pathway represents a novel therapeutic approach to enhance anti-cancer immunity by promoting both innate and adaptive immune responses. Unlike CD47, which is expressed ubiquitously, SIRPα expression is mainly restricted to myeloid cells and neurons. Therefore, compared to CD47-targeted therapies, targeting SIRPα may result in differential safety and efficacy profiles, potentially enabling lower effective doses and improved pharmacokinetics and pharmacodynamics. The development of effective SIRPα antagonists is restricted by polymorphisms within the CD47-binding domain of SIRPα, necessitating pan-allele reactive anti-SIRPα antibodies for therapeutic intervention in diverse patient populations. We immunized wild-type and human antibody transgenic chickens with a multi-allele and multi-species SIRPα regimen in order to discover pan-allelic and pan-mammalian reactive anti-SIRPα antibodies suitable for clinical translation. A total of 200 antibodies were isolated and screened for SIRPα reactivity from which approximately 70 antibodies with diverse SIRPα binding profiles, sequence families, and epitopes were selected for further characterization. A subset of anti-SIRPα antibodies bound to both human SIRPα v1 and v2 alleles with high affinity ranging from low nanomolar to picomolar, potently antagonized the CD47/SIRPα interaction, and potentiated macrophage-mediated antibody-dependent cellular phagocytosis in vitro. X-ray crystal structures of five anti-SIRPα antigen-binding fragments, each with unique epitopes, in complex with SIRPα (PDB codes 6NMV, 6NMU, 6NMT, 6NMS, and 6NMR) are reported. Furthermore, some of the anti-SIRPα antibodies cross-react with cynomolgus SIRPα and various mouse SIRPα alleles (BALB/c, NOD, BL/6), which can facilitate preclinical to clinical development. These properties provide an attractive rationale to advance the development of these anti-SIRPα antibodies as a novel therapy for advanced malignancies.

Abbreviations: ADCC: antibody-dependent cellular cytotoxicity; ADCP: antibody-dependent cellular phagocytosis; CFSE: carboxyfluorescein succinimidyl ester; Fab: fragment antigen binding; Fc: fragment crystallizable; FcYR: Fcy receptor; Ig: immunoglobulin; IND: investigational new drug; MDMO: monocyte-derived macrophage; NOD: non-obese diabetic; scFv: single chain fragment variable; SCID: severe combined immunodeficiency; SIRP: signal-regulatory protein

Introduction
Immune evasion is a hallmark of cancer, and therapeutic interventions that stimulate immune responses against tumors have shown remarkable clinical efficacy in diverse cancers. In particular, antibodies targeting the T cell inhibitory receptors PD-1 and CTLA-4 are capable of inducing long term, durable antitumor immunity in humans by stimulating the adaptive arm of the immune system. However, many patients fail to respond or develop resistance to T cell checkpoint therapy because tumors exploit multiple mechanisms to avoid immune detection and destruction, including the suppression of innate immunity. Combination therapies targeting non-redundant pathways that restrain antitumor immunity can dramatically improve response rates.

Signal-regulatory protein α (SIRPα) is an innate immune checkpoint receptor expressed primarily on myeloid cells, including monocytes, macrophages, dendritic cells (DCs), and neutrophils. SIRPα suppresses innate immunity upon interaction with its ligand, CD47. CD47 is broadly expressed on normal tissues and is up-regulated by virtually all human tumors to escape macrophage recognition and programmed cell removal. Inhibitory signals delivered by CD47 through SIRPα dampen FcyR-dependent antibody effector functions, including macrophage and neutrophil-mediated antibody-dependent cellular phagocytosis (ADCP) and cytotoxicity (ADCC), limiting the induction of antibody-dependent innate immunity and promoting resistance to antitumor antibody therapy.
Antagonizing the CD47/SIRPa interaction has a profound impact on potentiation of macrophage and DC phagocytosis of antibody-opsonized tumor cells, which in turn can prime antitumor CD8+ T cell responses, linking innate and adaptive immunity to anti-CD47 therapy. Beyond augmenting phagocytosis, disrupting the CD47/SIRPa interaction triggers numerous immunological responses that promote innate and adaptive antitumor immunity, including enhanced DC activation, a reduction in myeloid-driven immune suppression, and stimulation of type-I and type-II interferon responses. When combined with either tumor antigen-specific or immunomodulatory antibodies targeting T cell inhibitory receptors, CD47/SIRPa antagonists dramatically improve response rates across numerous xenogeneic and syngeneic mouse cancer models, resulting in durable long-term tumor immunity. Collectively, these preclinical results provide compelling evidence to support clinical evaluation of CD47/SIRPa antagonists in combination with antitumor or checkpoint antibodies. A variety of CD47 antagonists are under evaluation in the clinic. Promising activity was recently reported for an anti-CD47 antibody used in combination with rituximab for the treatment of lymphoma. In addition, the CD47 antagonist ALX148, a high-affinity SIRPa variant fused to an inactive Fc domain, has demonstrated a favorable safety profile and preliminary anti-cancer activity in the clinic when used in combination with pembrolizumab and trastuzumab for the treatment of solid tumors.

Disrupting the CD47/SIRPa interaction initially focused on targeting CD47 due to its ubiquitous expression on human tumors; however, several limitations associated with targeting CD47 may be circumvented by targeting SIRPa. The broad tissue distribution of CD47 creates a large antigen sink and promotes target-mediated clearance of anti-CD47 antibodies. In contrast, SIRPa expression is predominately restricted to myeloid cells; therefore, targeting SIRPa enables reduced dosing to achieve maximal receptor occupancy and improved pharmacokinetic and pharmacodynamic (PK/PD) properties. Furthermore, anti-CD47 antibodies capable of triggering Fc effector functions cause dose-limiting toxicities, including anemia and thrombocytopenia due to CD47 expression on red blood cells and platelets. Although we previously demonstrated that safety liabilities associated with anti-CD47 therapy can be avoided by Fc mutations that abrogate FcγR and complement (C1q) binding, it is of interest to study similarities and differences of an orthogonal approach to antagonize the SIRPa/CD47 axis by targeting SIRPa.

SIRPa belongs to the SIRP family of immunoreceptors that include the highly homologous activating receptor SIRPβ1 and the decoy receptor SIRPγ. Although CD47 is highly conserved, extensive polymorphisms localized to the CD47-binding IgV domain of SIRPa have been reported in numerous ethnic groups. Initial investigation of SIRPa polymorphisms in humans identified 10 allelic variants of SIRPa with two prevalent alleles, v1 and v2, shared between diverse ethnic groups and eight additional alleles with population-specific distributions of unknown frequency. More recently, Treffers et al. quantified SIRPa polymorphisms in Caucasians and identified only the two prevalent SIRPa variants, v1 and v2, within this population. Whereas genetic variation of SIRPa does not seem to affect intrinsic phagocytic function, activation of a single functional SIRPa variant in heterozygote macrophages is sufficient to inhibit antibody-dependent effector functions. Thus, effective therapeutic targeting of SIRPa across diverse patient populations requires pan-allelic anti-SIRPa antibodies.

We describe the discovery and characterization of a panel of wild-type, chimeric, and fully human anti-SIRPa monoclonal antibodies from chickens that exhibit high affinity, broad epitope coverage, and species cross-reactivity against mouse, monkey, and human SIRPa alleles. Guided by analysis of SIRPa polymorphisms across diverse human populations, we immunized chickens with allele and species-specific variants of SIRPa and screened antibody-secreting B cells to identify anti-SIRPa antibodies suitable for clinical translation. In total, 200 unique anti-SIRPa antibodies were identified and screened for binding to human, monkey, and mouse SIRPa, human SIRPβ and SIRPy, and for the ability to block the interaction between CD47 and SIRPa. Epitope binning and x-ray crystallography identified six distinct SIRPa epitopes, including epitopes that highly or partially overlap with the CD47 binding site, as well as epitopes that are distal from CD47. A subset of anti-SIRPa antibodies were found to bind with high affinity (nM to pM) to SIRPa v1 and v2 alleles, cross-react with monkey and mouse SIRPa, potently antagonize the CD47/SIRPa interaction, and enhance macrophage phagocytosis of antibody-opsonized tumor cells. Thus, the anti-SIRPa antibodies described herein represent promising candidates for targeting the CD47/SIRPa immunoevasion pathway for the treatment of human cancers by unleashing innate and adaptive immune responses.

**Results**

**Two SIRPa allelic variants are prevalent in diverse human populations**

The distribution and frequency of SIRPa variants across population and ethnic groups are not well characterized. Successful therapeutic targeting of SIRPa in diverse patient populations irrespective of SIRPa genotype necessitates pan-allelic anti-SIRPa antibodies that cross-react with all relevant SIRPa alleles. To aid in the design of a pan-allelic anti-SIRPa antibody discovery strategy, we first sought to determine the distribution and frequency of SIRPa polymorphic variants in human populations. We initially turned to the 1000 Genome Project, which has the largest public repository of sequenced human genomes (http://www.internationalgenome.org/home), and performed a comprehensive bioinformatic analyses of the SIRPA gene from 2535 individuals from the Phase 3 dataset of the 1000 Genome Project. As an orthogonal confirmation, we selected 510 individuals representing different populations from the above Phase 3 project, procured the respective DNA samples, and performed Sanger sequencing of exon 3 the SIRPA gene of these individuals. In agreement with Treffers et al., our bioinformatic analyses of SIRPa sequences from 2535 individuals and Sanger sequencing of 510 samples identified only two SIRPa variants, v1 and v2 (Table S1), represented as three allelic groups: homozygous v1/v1, homozygous v2/v2, and heterozygous v1/v2.
Examples of the detailed sequence analyses are described in Fig. S1. This contrasts with data reported by Takenaka et al. who identified eight additional allelic variants besides v1 and v2. Since eight of these allelic variants and individuals analyzed by Takenaka et al. were also coincidentally part of the Phase 3 dataset, we acquired the identical eight samples and carried out Sanger sequencing to confirm their allelic identities. Indeed, our results further confirmed that these samples are either homozygotes (v1/v1 or v2/v2) or heterozygotes (v1/v2).

Next, we determined the distribution and frequency of the SIRPa v1 and v2 allelic groups in various populations and their respective sub-populations (Figure 1(a,b)). The distribution of v1/v2 heterozygotes amongst the five super populations, European (EUR), American (AMR), East Asian (EAS), African (AFR) and South Asian (SAS), is similar and ranges from 42.0% to 47.2%. The East Asian population has a significantly higher number of v2/v2 than v1/v1 homozygotes occurring at a frequency of 42.3% and 13.3%, respectively, whereas the African, European, American, and South Asian populations had a moderately higher number of v1/v1 than v2/v2 homozygotes, with frequency ranges of 30.3–49.1% and 8.9–24.2%, respectively. The distribution of the three allelic variants within American, African, East Asian, South Asian and European sub-populations is similar to their respective super population, with the exception of the Peruvian (PEL) sub-population, which has a higher percentage of v2/v2 relative to v1/v1 homozygotes compared to the other American sub-populations (Figure 1(b)). Despite the observed distribution and frequency, we conclude only two SIRPa allelic variants v1 and v2 are present among the diverse populations analyzed in this study.

**Chicken immunization and GEM screen to isolate pan-allelic and -mammalian reactive anti-SIRPa antibodies**

Based on our results from SIRPa polymorphism analyses, it is critical that anti-SIRPa antibodies are capable of binding both SIRPa v1 and v2 alleles to be useful for clinical development. In addition, to facilitate rapid preclinical to clinical translation, we sought to discover anti-SIRPa antibodies that also cross-react with mouse SIRPa alleles from strains commonly used for syngeneic and xenogeneic tumor models (e.g., NOD/SCID, BALB/c, C57BL/6), and cross-react with cynomolgus monkey SIRPa for toxicology studies that may enable an investigational new drug (IND) application. Based upon SIRPa sequence homology (Table 1, Fig. S2 and Fig. S3), it may be challenging to obtain human, cynomolgus monkey, and mouse cross-reactive antibodies through traditional mouse immunization methods. Chickens are an attractive alternative to mice because they are phylogenetically distant from humans and produce antibodies of high affinity and specificity that can recognize unique epitopes not accessible to mice. Moreover, pan-mammalian-reactive anti-SIRPa antibodies are more likely to be discovered in chickens given the low homology between chicken SIRPa and the human and mouse orthologs (Table 1). The workflow for using chicken for immunization and antibody discovery is depicted in Figure 2(a).

To generate pan-allelic and species cross-reactive anti-SIRPa α antibodies, we immunized wild-type and transgenic chickens with the extracellular IgV domain of human SIRPa allele v1, which is the sole extracellular domain that mediates interaction with CD47, followed by boosts that alternate between human SIRPa allele (v1 vs v2) and/or species (mouse NOD or 129 vs. human SIRPa) in order to drive antibody responses toward a cross-reactive repertoire (Table 2). Wild-type and two different transgenic chickens were used for immunization: SynVH chickens which contain humanized VH immunoglobulin (Ig) repertoires paired with the natural chicken light chain repertoire, and OmniChickens, which contain humanized VH and VL Ig repertoires. In total, eight immunized chickens produced high titer antibodies against SIRPa v1, v2 and mouse SIRPa (Table 2, Figure 2(b)) from which splenocytes were harvested, and single antibody-
secreting B-lineage cells were screened for reactivity toward SIRPα using a gel-encapsulated microenvironment (GEM) assay. The GEM assay consists of a single-antibody secreting B-cell encapsulated in a droplet containing up to three different fluorescent reporter beads, each coated with a target antigen of interest (Figure 2(a)). B-cell clones that produce antibodies that bind to the immobilized targets were detected with a secondary antibody against chicken IgY, visualized via fluorescent microscopy, isolated, and sequenced. Various antigen-coated bead combinations were used to facilitate the discovery of anti-SIRPα antibodies with unique binding profiles (Table 2). For instance, to isolate pan-allelic and species-cross reactive antibodies that bind human SIRPα v1, human SIRPα v2, and mouse SIRPα, a triple-bead combination was used where each bead was individually coated with the respective antigen, and only B-cells producing antibodies that react with all three antigen-coated beads were recovered. Additional GEM screens were designed to distinguish
between antibodies that block the SIRPa/CD47 interaction and non-blocking antibodies via beads coated with SIRPa pre-complexed with CD47. Due to the weak affinity between wild-type SIRPa and CD47, we used engineered, high-affinity versions of SIRPa v1 and SIRPa v2 to ensure stability of the CD47/SIRPa complex and maximize the likelihood of identifying antibodies that bind SIRPa while in complex with CD47 (i.e., non-blocking antibodies). Conversely, blocking antibodies were identified by screening for clones that bind SIRPa but not the CD47/SIRPa complex, an indication that the antibody and CD47 bind overlapping epitopes on SIRPa. Through various GEM screens of lymphocytes prepared from immunized chickens (Table 2), over 200 unique anti-SIRPa antibody clones were identified. The V genes from each chicken antibody were reformatted into a single-chain variable fragment (scFv)-Fc fusion as described in Materials and Methods and produced recombinantly in HEK293FS for characterization by surface plasmon resonance (SPR) as described below.

**Chicken immunization yields anti-SIRPa antibodies with diverse binding properties, SIRP reactivity, and broad epitope coverage**

We first characterized the binding kinetics and specificity of anti-SIRPa scFv-Fc fusions toward a panel of SIRPs including human SIRPa v1 and v2, cynomolgus monkey SIRPa, mouse SIRPa (m129, NOD, BL6 alleles), human SIRPy, and human SIRPβ1. We performed a single concentration off-rate screen to triage anti-SIRPa scFv-Fc fusions based on species and allelic specificity, as well as cross-reactivity toward SIRPy and SIRPβ1. Most anti-SIRPa scFv-Fc fusions were found to bind both human SIRPa v1 and v2 alleles and cross-react with cynomolgus monkey and mouse SIRPa (Table S2), in agreement with the designed immunization strategy and GEM screens. In addition to pan-allelic and species cross-reactive anti-SIRPa antibodies, we identified a subset of allele-specific and species-restricted anti-SIRPa antibodies with specificity for hSIRPa v1 (clones 1, 123, 179, and 194) or hSIRPa v2 (clone 110). In general, most anti-SIRPa antibodies also bound SIRPβ1 and SIRPy, which was expected given the high degree of homology among SIRP family proteins (Fig. S4).

However, a small number of anti-SIRPa antibodies were identified that bind SIRPa and SIRPy but not SIRPβ1 (clones 1, 9, 93, 106), SIRPa and SIRPβ1 but not SIRPy (clones 173, 174), and one specific for SIRPa with limited binding to SIRPβ1 and SIRPy (clone 179). The specificity of anti-SIRP antibodies for SIRPa, SIRPβ, and SIRPy determined by SPR agrees with the reactivity of the anti-SIRP antibodies to various immune cell populations within human peripheral blood, which differ in expression of SIRPa, SIRPβ, and SIRPy (Fig. S7). Although outside the scope of this research, anti-SIRPa antibodies with differential specificity for SIRPa, β, and γ may be useful tools to further explore the biology of the SIRP family of immunoreceptors.

Next, we determined the ability of anti-SIRPa scFv-Fc fusions to block the interaction between SIRPa and CD47. A competitive SPR-based binding assay was used whereby blocking and non-blocking antibodies were identified based upon their ability to bind SIRPa while in complex with CD47. Anti-SIRPa antibodies were first captured on a chip and increasing concentrations of CD47 (0 to 1500 nM) were added to a constant concentration of the high-affinity SIRPa v1 variant CV1 (100 nM) to pre-assemble the CD47:CV1 complex prior to injection over the antibody immobilized on a chip (Figure 3). At saturating concentrations of CD47 (>100 nM), antibodies that bind overlapping epitopes on SIRPa (blocking) fail to bind the SIRPa/CD47 complex, whereas antibodies that bind non-competitive epitopes (non-blocking) form a classical sandwich with the SIRPa/CD47 complex. A number of blocking and non-blocking antibodies were identified using this screen, as summarized in Table S2, and representative sensorgrams of a blocking and non-blocking antibody are depicted in Figure 3(a and b), respectively. In addition to blockers and non-blockers, a third category of anti-SIRP antibodies was identified, termed kick-offs, that form a transient complex between antibody:SIRPa:CD47 prior to displacement of CD47 from antibody-bound SIRPa (Figure 3(c)). These antibodies bind SIRPa at a CD47 adjacent or minimally overlapping epitope and trigger antigen exchange between antibody and CD47. This mechanism is supported by structural analysis presented below.

To determine the diversity of epitopes recognized by the isolated anti-SIRPa antibodies, we performed epitope binning using a classical sandwich-based SPR assay. Binning experiments were conducted by immobilizing each anti-SIRPa antibody (ligand)
followed by capture of the recombinant SIRPα antigen and the pairwise interrogation of an in-solution antibody (analyte) binding to the antibody-captured SIRPα antigen. Epitope binning was performed again by reversing the mAb ligand/analyte orientation to validate the data set. A sorted heat map representing the epitope binning results for a panel of anti-SIRPα antibodies is shown in Figure 4(a). For simplicity, only representative antibodies within each bin are shown. Overall, the anti-SIRPα antibodies can be divided into six distinct epitope bins: blocking antibodies (bin 1), kick-off antibodies (bin 2), and non-blocking antibodies that subdivide into four bins (bin 3, 4, 5, and 6). The dendrogram showed that anti-SIRPα antibodies within the respective bins have diverse VH/VL sequences (Figure 4(b)). To represent these cross-competition matrix relationships in a different dimension, a node plot was generated to emphasize the interconnectivities within and between each epitope bin, sequence diversity within each bin, SIRP reactivity, and the respective chicken from which the antibodies were isolated (Figure 4(c)). Interestingly, certain bins contain antibodies that segregate into diverse sequence groups and originate from different chickens, whereas other bins are sequence family and source specific. For instance, blocking antibodies (bin 1) were isolated from wild-type, SynVH, and OmniChickens with five distinct sequence lineages, whereas kick-off antibodies (bin 2) were only identified from OmniChickens and represent a single,
related sequence family (Figure 4(c)). Non-blocking antibodies segregated into four distinct bins (bins 3, 4, 5, and 6) with diverse sequence groups, SIRP reactivity, and interconnectivity between the various bins.

Epitope binning experiments also indicate anti-SIRPα antibodies in bin 1 do not cross-block anti-SIRPα antibodies in the other five bins, whereas anti-SIRPα antibodies in bins 2, 3, 4, 5, and 6 cross-block each other (Figure 4(a, c)). Therefore, anti-SIRPα antibodies in bin 1 are expected to bind non-overlapping epitopes compared to anti-SIRPα antibodies from the other bins. On the other hand, anti-SIRPα antibodies in bins 2, 3, 4, 5, and 6 are expected to share binding epitopes based on their cross-competition network. For instance, anti-SIRPα antibodies in bin 3 are expected to share certain binding site residues with anti-SIRPα antibodies in bin 5 but will share a different and unique set of overlapping binding residues with anti-SIRPα antibodies in bins 4 and 6, respectively. These observations were subsequently confirmed by structural analysis (Figure 5).

In summary, pan-allele and -mammalian reactive anti-SIRPα blocking and non-blocking antibodies (blue nodes) could be identified from both wild-type and transgenic chickens; the use of multiple chickens with different Ig repertoires enabled the discovery of a collection of anti-SIRPα antibodies with broad epitope coverage and sequence diversity.

Crystal structures of anti-SIRPα Fab fragments in complex with SIRPα

To further confirm results from epitope binning and map the binding site details, as well as to elucidate the structural mechanisms underlying the effects of anti-SIRPα antibodies, we determined the crystal structures of representative anti-SIRPα Fabs from epitope bins 1–5 in complex with the Iγ V domain of human SIRPα v1. The antibodies include the blocking antibody 119 (bin 1), kick-off antibody 115 (bin 2), and non-blocking antibodies 136 (bin 3), 3 (bin 4), and 218 (bin 5). High-resolution crystals (1.83–2.68 Å) were obtained for all fiveFab:SIRPα complexes, and the corresponding structures were solved by molecular replacement35 (Figure 5(a), Table S4).

The anti-SIRPα blocking antibody clone 119 (bin 1) binds on top of SIRPα at an epitope highly overlapping that of CD47, in agreement with the antagonistic properties of clone 119 (Figure 5(b)). Although the binding geometries of CD47 and clone 119 to SIRPα are different, both proteins interact with a number of shared residues on SIRPα distributed throughout the binding interfaces (Figure 5(b,c)). Clone 119 binds SIRPα in a “top-down” orientation inserting its CDR-H3 loop into a central pocket of SIRPα formed by the BC, CD, and DE loops (Figure 5(b)), occupying the same site as the CD47 N-terminal pyroglutamate (pE), which contributes significantly to interaction between CD47 and SIRPα, whereas CD47 binds SIRPα in a “lying-down” orientation inserting its FG loop into a wide groove on the surface of SIRPα.35

The non-blocking antibodies 3, 136, and 218 bind SIRPα at regions distal from the CD47 binding site and do not overlap with any residues on SIRPα involved in either CD47 or clone 119 binding (Figure 5(a, c)), consistent with results obtained from epitope binning (Figure 4(a, c)). Anti-SIRPα clones 3, 136, and 218 interact with three unique but interconnected epitopes on SIRPα (Figure 5(c)). Clone 136 occupies a central SIRPα epitope flanked on opposing sides by clones 3 and 218, which bind distinct epitopes on SIRPα that partially overlap with clone 136, but not with each other. These crystallographic findings are consistent with the cross-competition network between clone 136 (bin 3), clone 3 (bin 4), and clone 218 (bin 5). Clone 136 competes with both clone 3 and 218 for SIRPα binding, whereas clones 3 and 218 compete with clone 136, but not with each other (Figure 4(a, c)).

Interestingly, the “kick-off” antibody clone 115 binds SIRPα directly underneath CD47 at a site mostly independent from that of CD47, with the exception of one residue localized to the C′D loop of SIRPα, Glu54, which is shared by both 115 and CD47 (Figure 5(c, d)). Superposition of the CD47:SIRPα and 115:SIRPα interfaces reveals remodeling of the C′D loop to an orientation that is favorable for binding to its respective ligand, as well as potential steric clashes between clone 115 and CD47 that could prevent CD47 from remaining bound to SIRPα upon antibody association (Figure 5(d)). It is conceivable that clone 115 first engages SIRPα while bound to CD47, potentially initiated by interactions between clone 115 and SIRPα that are distal from CD47, which ultimately leads to displacement of CD47 due to steric clashes between the heavy chain framework 3 regions (HC-FR3) of clone 115 and C′C′′ loop of CD47 (Figure 5(d)). This agrees with results from the SPR screen, where a transient increase in resonance was observed, indicating formation of the ternary complex between clone 115:CD47:SIRPα, and subsequent decrease in resonance consistent with the displacement of CD47 from the antibody/SIRPα complex (Figure 3(c)). Similar allosteric and displacement effects of an anti-IL-2 antibody that modulates cytokine–receptor interactions have been described36 as well as for anti-EGFR antibodies that target closely adjacent epitopes.33 In addition to overlapping epitopes with CD47, clone 115 partially overlaps with clone 218 (Figure 5(a) and Fig. S5), consistent with results obtained from epitope binning (Figure 4(a, c)).

We solved the structures of anti-SIRP antibodies in complex with the hSIRPα v1 allele; however, the structures of SIRPα v1 and v2 are highly conserved35 and only 1 or 2 of the 13 polymorphic residues contribute interactions with the anti-SIRPα antibodies (Table S3). Therefore, we suspect the antibodies will bind hSIRPα v2 in a similar orientation, although this needs to be validated through future crystallographic analyses.

Anti-SIRPα antibodies bind with high affinity to SIRPα

Based on epitope binning and mapping, SIRPα reactivity, and sequence diversity, we selected a subset of antibody clones for expression as full-length IgG molecules for further characterization. Binding affinities (Kd, M) as determined by SPR of representative anti-SIRPα antibodies from each epitope bin are summarized in Table 3. All antibodies bound to human SIRPα v1 and v2 with high affinity ranging from low nanomolar to picomolar. To facilitate clinical development, we prioritized
Figure 5. Crystal structures of anti-SIRPα antibodies bound to the IgV-domain of hSIRPα v1. (a) Structure of the SIRPα (pink)-CD47 (teal) complex superimposed with the anti-SIRPα blocking antibody Fab clone 119 (blue), non-blocking antibody Fabs clones 3 (pale pink), 136 (grey), and 218 (purple), and kick-off antibody Fab 115 (light green). (b) Overlay of the CD47/SIRPα complex and the blocking antibody clone 119 complex with a detailed view of CDR-H3 insertion into SIRPα pocket shown on the right. (c) Depiction of SIRPα (pink) epitopes bound by CD47 (teal) and anti-SIRPα antibody clones 119 (blue), 3 (pale pink), 136 (grey), 218 (purple), and 115 (light green). Residues shared between the blocking (119) and kick-off (115) antibodies and CD47 are colored yellow. Venn diagrams adjacent to each surface map indicate the relative extent of overlap between the blocking Fab 119 anti-SIRPα antibody, SIRPα, and CD47. For non-blocking antibodies, the yellow and white in the Venn diagrams indicate the overlap of epitopes between Fab 3, 136, and 218. (d) Overlay of the kick-off antibody clone Fab 115 (light green) and CD47 (teal) in complex with SIRPα (pink). The inset to the right shows the position of the CD loop of SIRPα in the CD47-bound (pink) complex or the Fab 115-bound (orange) complex. The Glu 54 residues is modeled in the CD loop to highlight the varying position depending on whether the binding partner is CD47 or Fab 115.
anti-SIRPα antibodies that bind similarly to both human SIRPα alleles and to cynomolgus SIRPα. The blocking antibody clones 21, 119, and 135 bind human SIRPα v1 and v2 alleles and cynomolgus SIRPα with a K_D of ~1 pM and 100 pM, respectively (Figure 6(a, b)). Clones 119 and 135 potently antagonize the SIRPα/CD47 interaction with an IC_{50} of ~0.3 nM (Figure 6(d)). Whereas clones 119 and 135 are specific for human and cynomolgus monkey SIRPα, clone 21 cross-reacts with mouse SIRPα alleles, albeit with somewhat reduced affinity (K_D ~ 0.5–1 nM) (Table 3). In addition, the non-blocking anti-SIRPα antibody clone 136 binds human SIRPα v1 and v2 alleles and cynomolgus SIRPα similarly with a K_D of ~1 nM. Clone 136 also cross-reacts with mouse SIRPα alleles with affinities comparable to that of human SIRPα (~1 nM). Of the antibodies that bind human and cynomolgus SIRPα, three also bind with high affinity to mouse SIRPα alleles from NOD, C57BL/6, and BALB/c (Table 3). High-affinity binding of anti-SIRPα antibodies to all three mouse SIRPα alleles are particularly attractive as this enables the interrogation of SIRPα antagonism across...
diverse preclinical mouse xenogeneic and syngeneic cancer models in the NOD/SCID, C57BL/6, BALB/c backgrounds. In summary, a large panel of antibodies with diverse binding specificities toward human, cynomolgus, and mouse SIRPα, as well as SIRP isoforms (SIRPβ1, SIRPγ), broad epitope coverage, and antagonistic properties were successfully identified in this study.

**Anti-SIRPα antibodies potentiate macrophage phagocytosis of human tumor cells**

Next, we evaluated the ability of anti-SIRPα antibodies to potentiate macrophage-mediated ADCP in combination with tumor-specific antibodies. We mutated anti-SIRPα antibody Fc-domains to abrogate binding to all FcγRs and complement in order to decouple potential FcγR- and complement-dependent contributions of anti-SIRPα antibodies to ADCP from direct inhibition of SIRPα signaling. Human monocyte-derived macrophages were incubated with carboxyfluorescein succinimidyl ester (CFSE)-labeled DLD-1 tumor cells opsonized with the tumor antigen-specific (anti-epidermal growth factor receptor (EGFR)) antibody cetuximab alone or in combination with increasing concentrations of anti-SIRPα blocking (clone 119) or non-blocking (clone 136) antibodies and phagocytosis was quantified by flow cytometry. Untreated DLD-1 cells were poorly phagocytosed, but treatment with cetuximab induced a significant increase in macrophage phagocytosis, which was further enhanced in a dose-dependent manner by the SIRPα antagonist (blocking) antibody clone 119 (Figure 7(a)). Somewhat surprisingly, the non-blocking anti-SIRPα antibody clone 136 also potentiated phagocytosis in combination with cetuximab (Figure 7(a)). Enhancement of phagocytosis by non-blocking anti-SIRPα antibodies was not specific to clone 136. All anti-SIRPα non-blocking antibodies, irrespective of epitope, potentiated cetuximab-mediated phagocytosis, albeit with varying degrees of potency (Figure 7(b)). Potentiation of phagocytosis by both blocking and non-blocking anti-SIRPα antibodies was not dependent on the presence of an Fc domain, as F(ab’)2 fragments of clone 21 (blocking) and clone 136 (non-blocking) similarly enhanced phagocytosis compared to their full-length IgG counterparts (Figure 7(c)). Treatment with either intact anti-SIRPα antibodies or F(ab’)2 fragments of the non-blocking antibodies had little to no impact on macrophage cell surface SIRPα levels (Fig. S6), indicating that phagocytosis by non-blocking antibodies was not due to SIRPα downregulation. Anti-SIRPα blocking and non-blocking antibodies similarly enhanced macrophage phagocytosis of OE19 cells opsonized with the antitumor (anti-human epidermal growth factor receptor 2) antibody trastuzumab (Figure 7(b)).

**Figure 7.** Anti-SIRPα antibodies potentiate macrophage-mediated ADCP in vitro. (a) Phagocytosis of DLD-1 cells by human monocyte-derived macrophages treated with the tumor-specific, anti-EGFR antibody cetuximab alone (closed square) or in combination with anti-SIRPα blocking (clone 119) or non-blocking (clone 136) antibodies. (b) Bar graph depicting the EC50 of phagocytosis (as shown in a) of anti-SIRPα antibodies from various epitope bins. Bin 1 = blocking, bin 2 = kick-off, and bins 3–6 = non-blocking. Phagocytosis was conducted using DLD-1 cells as targets with cetuximab in combination with anti-SIRPα antibodies (black bars), or OE19 target cells with trastuzumab in combination with anti-SIRPα antibodies (grey bars). (c) Dose-dependent enhancement of DLD-1 phagocytosis by human monocyte-derived macrophages treated with cetuximab in combination with anti-SIRPα intact IgG antibodies (blocking clone 21 and non-blocking clone 136) or the corresponding F(ab’)2 fragments. (d) Macrophage phagocytosis of DLD-1 cells treated with cetuximab alone or in combination with the hSIRPα v1 allele-specific antibody or pan-allele reactive anti-SIRPα v1/v2 antibody clone 21 as a function of macrophage SIRPα genotype. Data are normalized to the maximum phagocytosis observed in the clone 21 group. Data in panels A, C, and D are the mean (n = 3), and error bars indicate SD. Dashed lines represent data fit to a log-agonist vs. response model in Prism.
phagocytosis of IgG-opsonized sheep red blood cells in vitro, although phagocytosis was enhanced only in the presence of secondary cross-linking antibodies, suggesting higher order SIRPβ clustering is necessary to promote phagocytosis. Nonetheless, to investigate the contribution of SIRPβ to anti-SIRP antibody-mediated macrophage phagocytosis, we profiled the human macrophages used in our assay for expression of SIRPa, SIRPβ, and SIRPγ, and conducted phagocytosis assays using anti-SIRPa antibodies that do not bind to SIRPβ: clone 179 (SIRPα specific), and clone 1 (SIRPα and SIRPγ specific). SIRPβ was expressed on human CD14+ monocytes but was not expressed on the monocyte-derived macrophages (MDMα) used in our assay (Fig. S8A). SIRPγ was expressed on CD3 + T cells, but not CD14+ monocytes or MDMα. The anti-SIRPa antibody clones 1 and 179, which do not bind SIRPβ, potentiated cetuximab-mediated macrophage phagocytosis of DLD-1 cells in a dose-dependent manner similar to the activity of the pan-SIRP antibody clone 21 (Fig. S8B). Collectively, our data indicate that the phagocytic activity of the anti-SIRP antibodies used in this study is mediated by SIRPa and not due to cross-reactivity with SIRPβ.

Furthermore, SIRPa allele cross-reactivity was crucial to the efficacy of anti-SIRPa antibodies (Figure 7(d)). The anti-SIRPa v1 allele-specific antibody potentiated tumor cell phagocytosis by v1/v1 homozygous macrophages but failed to enhance phagocytosis mediated by v1/v2 heterozygous or v2/v2 homozygous macrophages. In contrast, the pan-allele anti-SIRPa v1/v2 antibody potentiated ADCP independent of macrophage SIRPa genotype (Figure 7(d)). These data are consistent with that of Zhao et al. who demonstrated that a single functional allele of SIRPa was sufficient to inhibit neutrophil-mediated killing of antibody-opsonized tumor cells. Thus, therapeutic targeting of SIRPa requires pan-allelic antibodies in order to be useful in diverse patient populations.

Discussion
The CD47-SIRPa axis has emerged as a myeloid checkpoint pathway to be targeted for the treatment of human cancers, and an ensuing plethora of agents aimed at disrupting the CD47-SIRPa interaction have entered the clinic or are in preclinical development. We previously demonstrated that ALX148, a high-affinity variant of hSIRPa fused to an inactive Fc-domain of IgG, potently antagonizes CD47, is well tolerated in preclinical species and has a favorable safety profile in humans due to the lack of Fc-effector function, is efficacious in numerous xenogeneic and syngeneic mouse cancer models when used in combination with tumor-specific and checkpoint antibodies, and has promising preliminary antitumor activity in humans. ALX148 prevents SIRPa signaling by occupying CD47, both on the tumor and in the periphery. CD47 is broadly expressed and has numerous reported ligands and functions beyond SIRPa-dependent regulation of macrophages and dendritic cells. The functional differences between targeting SIRPa and CD47 are generally unknown in part due to a lack of specific reagents that antagonize SIRPa. Thus, we sought to generate and characterize anti-SIRPa antibodies with diverse properties in order to investigate SIRPa biology and extend our approach of antagonizing the CD47/SIRPa interaction as a treatment modality for cancer to SIRPa.

The development of effective SIRPa antagonists suitable for clinical translation has been challenging due to the polymorphic nature of SIRPa as well as a poor understanding of the allelic distribution and frequency of SIRPa across human populations. Zhao et al. previously demonstrated using pan-allelic or allele-specific anti-SIRPa blocking antibodies that antagonism of both SIRPa alleles was necessary to enhance trastuzumab-mediated ADCC when neutrophils from SIRPa v1/v2-heterozygous donors were used as effector cells. We observed a similar requirement for antagonism of both SIRPa alleles to enhance macrophage-mediated ADCP when v1/v2-heterozygous macrophages were used as effectors (Figure 7(d)), in agreement with results by Zhao et al. and extending these findings to macrophages. Given the high percentage of SIRPa v1/v2-heterozygous individuals across human populations (Figure 1), as well as the requirement for full SIRPa antagonism to maximize efficacy, anti-SIRPa antibodies should be capable of antagonizing both SIRPa alleles. Numerous, potent anti-SIRPa antibodies that bind to both human SIRPa alleles are reported in this study.

In addition to the need for pan-allelic antibodies, to facilitate preclinical development, antibodies directed against human SIRPa should be cross-reactive with cynomolgus monkey SIRPa for IND-enabling toxicology studies, and ideally cross-react with mouse SIRPa alleles to avoid the use of surrogates when investigating pharmacology. Only a few anti-human SIRPa antibodies have been described in the scientific literature. These antibodies were raised in mice, and therefore do not cross-react with mouse SIRPa. In order to generate pan-mammalian and pan-allelic anti-SIRPa antibodies, we immunized chickens, which are phylogenetically distinct from mice and humans, thereby increasing the probability of generating a productive antibody response against mouse and human immunogens. Using a multi-species and multi-allele immunization schedule and chickens with wild-type or human Ig repertoires, we identified a panel of wild-type, chimeric, or fully human anti-SIRPa blocking and non-blocking antibodies with broad specificities directed against the CD47-binding IgV domain of SIRPa. The isolated antibodies exhibited high-affinity binding to SIRPa with affinities ranging from low nM to low pM, and therefore additional affinity maturation was unnecessary. The panel of antibodies identified displayed broad epitope coverage, enabling the interrogation of the role of epitope on the function of anti-SIRPa antibodies.

The most well-known function of the SIRPa/CD47 interaction is the negative regulation of macrophage phagocytosis. Antibodies that block the interaction between CD47 and SIRPa promote macrophage phagocytosis of tumor cells by inhibiting SIRPa signaling and tipping the balance of pro- and anti-phagocytic signals. The anti-SIRPa blocking antibodies described herein potently potentiate macrophage-mediated ADCP of tumor cells, as expected based on the known effects of antagonizing the SIRPa/CD47 axis. Interestingly, we found that non-blocking antibodies directed against SIRPa also enhance macrophage phagocytosis (Figure 7). Enhancement of phagocytosis by non-blocking antibodies was independent of the five different epitopes on the SIRPa IgV-domain that are targeted by the
panel of antibodies we discovered. These data are in agreement with reports by Murata et al. who demonstrated that an anti-SIRPα non-blocking antibody that binds the Ig-C1-like domain of SIRPα also promoted macrophage phagocytosis, albeit to a lower extent than blocking antibodies, suggesting that phagocytosis mediated by non-blocking anti-SIRPα antibodies is not epitope or domain specific, but likely an intrinsic function of antibody-based targeting of SIRPα. Phagocytosis triggered by non-blocking antibodies directed against the SIRPα/CD47 axis appears to be specific to targeting SIRPα, as non-blocking antibodies directed against CD47 have no effect on macrophage phagocytosis. It has been speculated that SIRPα non-blocking antibodies promote phagocytosis through either SIRPα downregulation or the ‘scorpion effect’ where antibody binding to SIRPα permits Fc-domain binding and activation of FcγR signaling on the same cell. However, we observed little to no downregulation of SIRPα during the course of phagocytosis (Fig. S6). Furthermore, the antibodies used in our experiments were mutated to abrogate FcγR and complement binding, ruling out potential contributions of cis-interactions with activating or inhibitory FcγRs. In addition, F(ab')2 fragments of non-blocking anti-SIRPα antibodies, which lack an Fc domain, were equivalent to their corresponding full-length IgG molecule (Figure 7(c)). The activating receptor SIRPβ has been suggested to be a positive regulator of macrophage phagocytosis, however, the macrophages used in our experiments do not express SIRPβ or SIRPγ (Fig. S8A), therefore anti-SIRP antibody-mediated phagocytosis cannot be attributed to cross-reactivity with SIRPβ or SIRPγ. Collectively, these data suggest that alternative, yet unknown mechanisms are responsible for the potentiation of macrophage phagocytosis by anti-SIRPα antibodies that do not block the interaction with CD47. It is conceivable that antibody binding to SIRPα may restrict CD47-independent SIRPα tonic signaling, thereby promoting phagocytosis. The detailed mechanism by which SIRPα signaling influences macrophage phagocytosis is poorly understood. The broad panel of mechanisms described herein may be useful to interrogate such biological mechanisms and as promising therapeutics to treat human cancers.

Materials and Methods

Bioinformatic analyses of SIRPa polymorphisms

We performed in-depth bioinformatic investigation of IgV domain of the SIRPA gene using sequence data from 1000 Genome Project. For this, we downloaded genomic variants for 2535 sequenced genomes from the Phase 3 dataset present in vcf (variant calling files) from public database (http://www.internationalgenome.org/data#download) that span SIRPA gene (chr20:1,875,425–1,920,540, hg18 reference genome). Of 1722 variants in this region, 21 known variants that resulted in missense mutations were present in the IgV domain of the SIRPA gene. Errors in variant calls due to low coverage were fixed by customly written perl script. cDNA sequences of various samples were determined using fixed vcf files and translated to protein sequences by making changes in the consensus coding sequence (CCDS13022.1) of the SIRPA gene using customly written perl script. After which, the translated amino acid sequences in the IgV domain were then compared with EnsEMBL_V1 sequence (ENSP00000348307.3).

Sanger sequencing of selected human samples

Sanger sequencing of 510 samples from different populations were performed (Table S1). These samples were selected from different populations: Mexican Ancestry from Los Angeles USA (MXL), Yoruba in Ibadan, Nigeria (YRI), Utah Residents (CEPH) with Northern and Western European Ancestry (CEU), Colombians from Medellín, Colombia (CLM), British in England and Scotland (GBR), Han Chinese in Beijing, China (CHB), Bengali from Bangladesh (BEB), and Americans of African Ancestry in South West USA (ASW), Japanese in Tokyo, Japan (JPT). DNA samples for these populations were obtained from the NHGRI Sample Repository for Human Genetic Research at the Coriell Institute for Medical Research. DNA was quantified using picogreen assay and normalized to 10 ng/ml. PCR amplification of the target region (exon 3) was carried out using PCR primers pairs forward 5’-TGTCAGGTACGGGCTCCCT and reverse 5’-CACCAACACCTGTACATTGTCTC (IDT Technologies, Iowa City, USA) and KAPA Hyper polymerase (Roche Holding AG, Basel, CH). PCR amplification was performed using the reactions conditions as follows: after preheating at 95°C for 5 min, amplification consisted of 30 cycles at 98°C for 20 s, 68°C for 30 s, and a final extension at 72°C for 5 min. PCR products were purified using the AMPure® XP (Beckmann Coulter, Brea, CA) and quantified using the NanoDrop® (Thermo Fisher Scientific). While performing Sanger sequencing, we noticed the presence of three known deletions (rs138304215-delCT, rs749337996-delCT, and rs139878822-delCGA), and these deletions resulted in chromatograms that are not interpretable. Due to the complexity of these regions, five different Sanger sequencing reactions were performed using the following primers to generate conclusive Sanger sequencing data;

a) 5’-GGCTCCCCTTTTCGGAACATTCACACAG, b) 5’-GTGTAAGTTCGGGAAGGAGCCCGAT, c) 5’-GCTCCAGACTTAACTCCACGTCATCGG, d) 5’-CATGCTCCAGACTTAAACTCCACGTCAG and e) 5’-GTGTAAGTTCGGGAAGGAGCCCGTCT.

DNA (10 ng) was sequenced using the BigDye Terminator cycle sequencing kit (v3.1; Thermo Fisher Scientific). Following purification using the Centri-Sep Spin Columns (Thermo Fisher Scientific), the nucleotide sequences were determined using an ABI3730XL Genetic Analyzer (Thermo Fisher Scientific). Sequence data were aligned using Sequencer® DNA sequence analysis software (v5.2.4; Gene Codes Corporation, Ann Arbor, MI). All the Sanger sequencing results (Table S1) were found to be concordant with our bioinformatic analysis.

Generation of antigens for immunization and screening

The IgV domains of SIRPa antigens from four respective sources were generated for immunization as fusion to human IgG-Fc to increase immunogenicity. Specifically, they are human SIRPa v1 (NP_542970.1), SIRPa v2 (CAA71403.1),
mouse 129 SIRPα (162330193) and NOD SIRPα sequence as described in references \(^\text{42,43}\) and reported in Figure S2 and Figure S3. The Fc-fused proteins were expressed in Expi293 cells (Invitrogen) using standard manufacturer’s protocol. Expression cultures were typically grown for five days at 37°C in 8% CO\(_2\). Supernatants were harvested via centrifugation and sterile filtered. Proteins were affinity purified using MabSelect Sure LX resin (GE Healthcare). For SPR screening, the IgV domains of the respective SIRP were expressed in Expi293 cells as described above as either His-tagged or His-Avi-tagged fusions and purified using Ni-Sepharose 6 Fast Flow affinity purification (GE Healthcare). The panel of SIRP generated for SPR screening were the IgV domain from human SIRPα v1 (NP_542970.1), human SIRPα v2 (CAA71403.1), cynomolgus SIRPα (EHH65484.1), mouse 129 SIRPα (162330193), NOD/BALBc/C57BL/6 SIRPα (sequences as described in references 41 and 42 and reported in Figure S2 and Figure S3), and human SIRPγ (NP_061026.2) and human SIRPβ1 (NP_006056.2) (sequences as reported in Figure S4). The IgV domain of CD47 was generated as described in reference 12. The high-affinity SIRPα variant CV1 was generated as described in reference 14.

**Immunization of chickens**

In total, 19 chickens were immunized. Specifically, these include four wildtype White Leghorn chickens, 4 SynVH chickens, which are transgenic chickens containing VH from human and VL from chicken, \(^\text{31}\) and 11 chickens with fully human immunoglobulin loci called OmniChicken. \(^\text{30}\) The chickens were immunized with varied schedules having alternating doses and boosts of human SIRPα v1, human SIRPα v2 and mouse SIRPα (m129 or NOD). The immunization protocol was approved by the Institutional Animal Care and Use Committee. Sera were collected bi-weekly during the immunization to determine plasma titer by ELISA. In total, eight immunized birds with good final titers were selected for preparation of splenocytes and lymphocyte screenings using the GEM assay (Figure 2(b)). The immunization schemes for the selected birds are described in Table 2. For example, wildtype 21,288 bird was initially immunized with 100 µg human SIRPα v1 at week 1, boost with 50 µg of human SIRPα v2 at week 3, draw at week 4, boost with 50 µg of human SIRPα v1 at week 5, draw at week 6, boost with 50 µg of human SIRPα v2 at week 7, and draw at week 8.

**Screening single B cells using the GEM assay**

A single lymphocyte screening and recovery method, the GEM assay was used to isolate antigen-specific mAbs from immunized chicken. The GEM assay involves placing single mAb-secreting lymphocytes in proximity with reporter beads. The secreted mAb diffuses locally within the GEM and has the opportunity to bind to the reporter beads. Bound mAb is detected directly through the use of a fluorescent secondary mAb, anti-IgY Alexa 594 (Life Technologies A-11042). There were four beads used in this program: 1) a 5 µm latex bead coated with hSIRPα v1; 2) a 5 µm blue latex bead coated with hSIRPα (129, NOD or BALBc); 3) a 1.4 µm latex bead coated with hSIRPα v2, and 4) a 5 µm latex bead coated with CD47 followed by a mixture of high-affinity SIRPα v1 and v2. Three of the four beads were encapsulated with a single B cell from the chicken being screened depending on the objective of the screen. For example, if the goal of the screen was to ensure species cross-reactivity, then the beads encapsulated were 5 um hSIRPα v1, 1.4 um hSIRPα v2 and 5 um blue mSIRPα. Fresh beads were coated within a week of performing GEM assays. To coat beads, protein was diluted in phosphate-buffered saline (PBS). The diluted protein was added directly to the beads and incubated at 4°C overnight while rocking. Beads were washed with PBS and blocked with 3% filtered milk in PBS. Beads were washed and tested using reactive plasma from immunized chickens. GEMs were viewed on a Leica DMI 6000 B inverted fluorescent microscope.

**Cloning and expression of recombinant mAbs**

Cells secreting antigen-specific mAbs were isolated from the GEM assay, and their respective V genes were amplified by a two-step, semi-nested strategy as described. \(^\text{32}\) Briefly, the V-genes were cloned through RT PCR and cloned into the mammalian expression vector pF5a (Promega) in scFv-Fc format (IgG1-Fc isotype with effector attenuating Fc substitutions \(^\text{37,38,43}\) that ablate FcyR and complement binding). Plasmids containing recombinant scFv-Fc from the GEM harvests were transiently transfected into HEK293F (Thermo Fisher) and clonal supernatants were harvested. Supernatants were tested for binding activity by SPR described below. All clones that were confirmed as binding their respective targets were fully sequenced to avoid redundancies. Select clones were converted to full-length IgG1 molecules with effector attenuating Fc substitutions and produced in HEK293F.

**SPR Screening of Antibody Clones**

Binding of the antibody clones to various SIRP proteins was determined using SPR detection on a ProteOn XPR36 instrument (Bio-Rad, Hercules, CA) using PBS (pH 7.4) supplemented with 0.01% Tween-20 (PBS-T) as running buffer. The pre-filtered media containing the recombinant scFv-Fc were used directly for the assay. First, anti-human IgG Fc (BR-1008–39, GE Healthcare) was amine-coupled onto a GLC sensor chip (Bio-Rad, Cat. #1765011) to generate the capture surfaces for the antibodies. About 4000 RU per flow cell of immobilized anti-human IgG Fc is achieved. Each clone was screened using the same method as follows: 5–10 µL of pre-filtered media in 10 mM sodium acetate buffer (pH 4.5) was injected for 2 min at 30 µL/min; buffer flow for 1 min at 100 µL/min; SIRP analyte (100 nM) injected for 1 min at 100 µL/min, followed by a dissociation cycle of 10 min; regeneration of chip surface by flowing 3 M magnesium chloride for 1 min at 25 µL/min in both orientation; and buffer flow for 1 min at 100 µL/min. Biosensor data were double-referenced by subtracting the interspot data (containing no immobilized anti-human IgG Fc) from the reaction spot data (immobilized anti-human IgG Fc), and then subtracting the response of a buffer “blank” analyte injection from that of an analyte injection. Binding was fitted using a 1:1 Langmuir and \(k_\text{off}\) (1/s) values calculated. All SPR assays were performed at 25°C and all SPR assays described here used PBS-T as running buffer.
**Anti-SIRPα antibody screen to identify effect on the SIRPα/CD47 interaction**

To assess if antibodies can block binding of SIRPα to CD47, an SPR screen was carried out. Antibody capture was carried out using an anti-human IgG-Fc immobilized GLC surface prepared as described above. A SIRPα variant (CV1) engineered to bind CD47 with high nM affinity was generated for the crystallographic complex. The wildtype SIRPα variant was used in testing. 100 nM antibodies to SIRPα complexes were determined using a kinetic mode using an anti-SIRPα antibody and SIRPα variant (CV1) pre-mixed with CD47 at different concentrations of 0, 20, 50, 150, or 1500 nM. The binding affinities of anti-SIRPα antibodies were determined by subtracting the response of a buffer of interest from that of an analyte injection.

**Epitope binning**

Epitope binning was carried out using a classical sandwich approach using methods described by Abdiche et al. Anti-SIRPα antibodies were immobilized on a GLC chip, and then human SIRPα v1 was injected followed by a second anti-SIRPα antibody. The second antibody was able to bind the complex formed between the first anti-SIRPα antibody and SIRPα, the first and second antibodies were determined to bind different epitopes. The first antibody was not able to bond, the first and second antibodies were determined to share an epitope. The detailed components of the experiment are described as follows. First, anti-SIRPα antibodies were immobilized on GLC chips using a ProteOn Amine Coupling Kit. For the immobilization step, GLC chip was activated with EDAC/Sulpho-NHS diluted 1/100 for 300 s at 25 μL/min. Anti-SIRPα antibodies were diluted to 80 nM concentration in 10 mM sodium acetate buffer pH 4.5 and immobilized to the chip at 30 μL/min. The chip was inactivated with ethanolamine for 300 s at 25 μL/min. Anti-SIRPα antibodies were diluted to 80 nM concentration in 10 mM sodium acetate buffer pH 4.5 and immobilized to the chip at 30 μL/min for 50 s. The chip was inactivated with ethanolamine for 300 s at 25 μL/min. The IgV domain of SIRPα v1 was first injected at 100 μM for 60 s, followed by injection of the anti-SIRPα antibodies in testing (100–150 nM) at 100 μL/min for 60 s. The surfaces were regenerated with 2:1 v/v blend of Pierce IgG elution buffer/4 M NaCl. The resulting sensorsgrams were used to score and group the antibodies into different bins according to their binding profiles.

**Crystallization of anti-SIRPα Fab: SIRPα complexes**

The IgV domain of SIRPα v1 was generated for crystallography as previously described. A mutation N80A was introduced to produce a homogenous and non-glycosylated SIRPα v1 that would be most amenable for crystallization. The anti-SIRPα antibodies were generated as Fab fragments with a 6His-tag at the C-terminus of the truncated hinge domain. Both SIRPα v1 and the Fab fragments were expressed in Expi293 and purified using Ni-Sepharose 6 Fast Flow affinity purification (GE Healthcare) followed by gel filtration. The Fabs and SIRPα v1 proteins were purified individually prior to being complexed (with SIRPα v1 in molar excess) proceeded by a final SEC step to separate unbound proteins. The final formulation buffer is minimal with 10 mM Tris pH 7.5 and 50 mM NaCl. The purified Fabs and SIRPα complex sample is stable at 4°C and was concentrated to 10–12 mg/mL for crystallography.

The methods for the anti-SIRPα antibodies and SIRPα complex structure solution followed well-established principles of crystallography, beginning with sparse matrix crystallization trials. Conditions were selected from initial trials and optimized for formation of favorable crystals for harvest and synchrotron X-ray diffraction screening. Once a crystallization regime is established for one complex, the protocol can be followed for subsequent anti-SIRPα Fab antibodies: SIRPα complexes. Crystallization experiments used the sitting drop vapor diffusion technique for the initial sparse matrix screening and commercially available kits from Qiagen. Crystallization trials were set in varying ratios ranged in 1:1, 2:1, and 3:1 of anti-SIRPα Fab: SIRPα complex to crystallant in total volume of 1 μL in the well reservoir. The completed plates were sealed to allow vapor diffusion to occur and stored in a 12°C incubator. Crystallization of the five anti-SIRPα Fab: SIRPα complexes were achieved with derivatives of two main conditions as shown in Table S4. The detailed steps involved for crystal harvest, data collection, and processing, structure building and refinement are described in
the supplementary materials. The PDB codes for the structures generated are 6NMV, 6NMU, 6NMT, 6NMS, and 6NMR.

**Epitope mapping and superimposition analysis based on crystal structures**

Buried surface area of the antigen for the epitope was calculated as the difference between the solvent-accessible surface area of the antigen alone and antigen in complex with the Fab fragment of the antibody. The accessible surface area was calculated by the rolling ball method with a probe radius of 1.4 Å. Buried surface area is reported in Å² (Table S3). All Fab antibody: SIRPα complexes were aligned by superimposing the carbon atoms of SIRPα from each structure with the CD47: SIRPα complex (v1 variant) structure (PDB: 4CMM). Superimposition was performed using PYMOL. The calculated RMSD (0.50) between the aligned SIRPα structures in the complexes showed little variation, hence validating the overlay (Table S6). Therefore, the alignment of the SIRPα structures is credible to establish a reference point to analyze the varying binding epitopes of the Fab anti-SIRPα antibodies.

**Cell staining to determine binding profiles of anti-SIRP antibodies**

Peripheral blood mononuclear cells (PBMCs) were isolated from Trima residuals of healthy individuals (purchased from Vitalent) with Ficoll-Paque Plus (GE Cat. 17144003). CD14+ monocytes were isolated from PBMC by negative selection (Miltenyi Cat. 130–091-153) per manufacturer’s protocol. Monocyte-derived macrophages (MDM) were differentiated from CD14+ monocytes using macrophage colony-stimulating factor (M-CSF) (Miltenyi Cat. 130–096-491) (50 ng/mL) for 9 days in culture medium. Cells were stained with FcR block (Miltenyi Cat. 130–059-901) in PBS (Gibco Cat. 10010) + 0.5% bovine serum albumin (BSA) (Sigma Cat. 0096-14) was used to fix the fragments via Protein A. Cetuximab and trastuzumab were added at a concentration of 0.01–0.1 μg/ml for DLD-1 cells and trastuzumab was added at a concentration of 0.01 μg/ml for OE19 cells. F(ab')2 fragments were prepared using the Pierce F(ab')2 purification kit following the manufactures recommended protocol (ThermoFisher) and undigested IgG was purified away from F(ab')2 fragments via Protein A. Cetuximab and trastuzumab were produced in HEK293F using standard monoclonal antibody production methods. Sequences were obtained from the Drugbank (www.drugbank.ca), DB00072 and DB00002 for trastuzumab and cetuximab, respectively.

For flow cytometry, cells were incubated in human FcR Blocking Reagent (Miltenyi Biotec) and stained with fluorescein isothiocyanate (FITC)-labeled antibodies against CD33 (clone WM53, Biolegend) and CD206 (clone 15–2, Biolegend). To eliminate macrophage/target cell adhesion from analyses, antibody against CD326 (clone 9C4, Biolegend) was included for DLD-1 and OE19 cells. Furthermore, a pulse geometry gate of forward scatter signal area vs height was used to select for single cells. Fixable viability dye (Thermo Fisher Scientific) was used to identify live cells. Cells were analyzed on a FACS Canto II flow cytometer (BD Biosciences) with subsequent analysis using FlowJo software. Percent phagocytosis indicates the percentage of viable CD33+ CD206+ macrophages that stain negative for CD326 and positive for CFSE. When applicable, four parameter fit curves were generated with Prism 7 software (GraphPad).

**Cell-based SIRPα antagonism assay**

Antagonism of CD47 binding by anti-SIRPα antibodies was performed using CD47-Fc fluorescently labeled using the Alexa Fluor 647 Protein Labeling Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Alexa Fluor 647-labeled CD47-Fc at a concentration of 250 nM and fluorescently labeled anti-CD47 (Biolegend Cat. 325618) were added to 100,000 PBMCs in 100 μL volume of FACs buffer (PBS + 0.5% BSA) supplemented with a cocktail of human Fc block (Miltenyi Biotec). After 30 min on ice, cells were washed once in staining buffer. Anti-SIRPα was added at a concentration of 1.25 μM with 10-fold serial dilutions. After 30 min on ice, cells were washed twice in staining buffer and fixed in 0.5% paraformaldehyde. Cells were analyzed using a FACS Canto II (BD Biosciences), with subsequent data analysis and histogram plotting using FlowJo 10.7 and Prism 7 software (GraphPad).

**Disclosure statement**

These studies were sponsored by ALX Oncology. JS, JTS, ES, LD, OH, SEK, AC, TCK, HW, and JP are all employed by ALX Oncology and are...
References

1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14. doi:10.1016/j.cell.2015.03.030.
2. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–55. doi:10.1126/science.aar4060.
3. Moynihan KD, Irvine DJ. Roles for innate immunity in combination immunotherapies. Cancer Res. 2017;77(19):5215–21. doi:10.1158/0008-5472.CAN-17-1340.
4. Ho CCM, Guo N, Sockolosky JT, Ring AM, Weiskopf K, Özkan E, Mori Y, Weissman IL, García KC. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem. 2015;290(20):12650–63. doi:10.1074/jbc.M115.648220.
5. Barclay AN, Van Den Berg TK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25–50. doi:10.1146/annurev-immunol-031313-111645.
6. Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci. 2012;109(17):6662–67. doi:10.1073/pnas.1121623109.
7. Lange J, Skaletsky H, van Daalen SKM, Embry SL, Korver CM, Brown LG, Oates RD, Silber S, Repping S, Page DC. Isodentric Y chromosomes and sex disorders as byproducts of homologous recombination that maintains palindromes. Cell. 2009;138(5):855–69. doi:10.1016/j.cell.2009.07.042.
8. Sockolosky JT, Dougan M, Ingram JR, Ho CCM, Kauke MJ, Almo SC, Ploegh HL, Garcia KC. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016;113(19):E2646–E2654. doi:10.1073/pnas.1602468113.
9. Ge C, Du J, Zhao, L, Wang L, Liu Y, Li D, Yang Y, Zhou R, Zhao Y, Chai Z, et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci U S A. 2011;108(41):16968–7. doi:10.1073/pnas.1105270108.
10. Tseng D, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyaniishi M, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci. 2013;110(27):11103–08. doi:10.1073/pnas.1305569110.
11. Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu Y-X, Xu MM. CD47 blockade triggers T cell-mediated destruction of immunotherapy-resistant tumors. Nat Med. 2015;21(10):1209–15. doi:10.1038/nm.3931.
12. Kauder SE, Kuo TC, Harrabi O, Chen A, Sangalang E, Doyle L, Rocha SS, Bollini S, Han B, Sim J, et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS One. 2018;13(8):e0201832. doi:10.1371/journal.pone.0201832.
13. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Retseca D, Zabriskie MS, Zhang TV, Khorashad JS, Engvall EJ, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2017;31(5):1253–54. doi:10.1038/leu.2017.14.
14. Weiskopf K, Ring AM, Ho CCM, Volkmer J-P, Levin AM, Volkmer AK, Özkan E, Fernhoff NB, van de Rijn M, Weissman IL, et al. Engineered SIRPα variants as immunotherapeutic agents to anticancer antibodies. Science. 2013;341(6144):88–91. doi:10.1126/science.1238856.
15. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–713. doi:10.1016/j.cell.2010.07.044.
16. Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer J-P, George BM, Lietzmannayer M, McKenna KM, Naik T, McCarty A, et al.; Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage activation. Proc Natl Acad Sci U S A. 2017;114(49):E10578–E10585. doi:10.1073/pnas.1710877114.
17. Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer. 2017;76:100–9. doi:10.1016/j.ejca.2017.02.013.
18. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711–21. doi:10.1056/NEJMoa1807315.
19. Lakhani N, Lo Russo P, Chow LQ, Bang Y, Gainor J, Lee J, Chung H, Lee K, Hodi S, Fanning P, et al. A Phase I study of ALX148: CD47 blockade in combination with anticancer antibodies to bridge innate and adaptive immune responses for advanced malignancy [abstract]. Proceedings of the 33rd Annual Meeting of the Society for Immunotherapy of Cancer; 2018 Nov 7–11; Washington, DC, p Abstract nr P335.
20. Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesh N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL, et al. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci U S A. 2017;114(38):10184–89. doi:10.1073/pnas.1710776114.
21. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohsaka S, Volkmer J, et al. Preclinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10(9):e0137345. doi:10.1371/journal.pone.0137345.
22. Vernet M-A, Reymard S, Fizet A, Schaeffer J, Pannetier D, Guedj J, Lecomte G, Ovadya D, Martin R, Cohen JD, et al. Anti-CD47 antibodies enhance immune cell cytotoxicity towards cancer cells. Eur J Immunol. 2017;47(1):25–35. doi:10.1002/eji.201644226.
23. Vernet M-A, Reymard S, Fizet A, Schaeffer J, Pannetier D, Guedj J, Lecomte G, Ovadya D, Martin R, Cohen JD, et al. Anti-CD47 antibodies enhance immune cell cytotoxicity towards cancer cells. Eur J Immunol. 2017;47(1):25–35. doi:10.1002/eji.201644226.
